| The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component Y Liu, A Sattarzadeh, A Diepstra, L Visser, A van den Berg Seminars in cancer biology 24, 15-22, 2014 | 142 | 2014 |
| A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus W Cozen, MN Timofeeva, D Li, A Diepstra, D Hazelett, ... Nature communications 5 (1), 3856, 2014 | 104 | 2014 |
| The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing Y Liu, FR Abdul Razak, M Terpstra, FC Chan, A Saber, M Nijland, ... Leukemia 28 (11), 2248-2251, 2014 | 103 | 2014 |
| Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas JK Lue, SA Prabhu, Y Liu, Y Gonzalez, A Verma, PS Mundi, NA Abshiru, ... Clinical Cancer Research, 2019 | 71 | 2019 |
| IgG gene expression and its possible significance in prostate cancers Y Liu, Z Chen, N Niu, Q Chang, R Deng, C Korteweg, J Gu The Prostate 72 (6), 690-701, 2012 | 49 | 2012 |
| NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death Y Liu, P Mondello, T Erazo, NB Tannan, Z Asgari, E de Stanchina, ... Proceedings of the National Academy of Sciences 115 (47), 12034-12039, 2018 | 46 | 2018 |
| Immunoglobulin g (IgG) expression in human umbilical cord endothelial cells Y Zhao, Y Liu, Z Chen, C Korteweg, J Gu Journal of Histochemistry & Cytochemistry 59 (5), 474-488, 2011 | 42 | 2011 |
| Transcription factors E2A, FOXO1 and FOXP1 regulate recombination activating gene expression in cancer cells Z Chen, Y Xiao, J Zhang, J Li, Y Liu, Y Zhao, C Ma, J Luo, Y Qiu, G Huang, ... PLoS One 6 (5), e20475, 2011 | 38 | 2011 |
| BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors E Derenzini, P Mondello, T Erazo, A Portelinha, Y Liu, M Scallion, ... Cell Reports 24 (8), 2155-2166, 2018 | 35 | 2018 |
| Immunoglobulin G locus events in soft tissue sarcoma cell lines Z Chen, J Li, Y Xiao, J Zhang, Y Zhao, Y Liu, C Ma, Y Qiu, J Luo, G Huang, ... PLoS One 6 (6), e21276, 2011 | 11 | 2011 |
| PML nuclear bodies and SATB1 are associated with HLA class I expression in EBV+ Hodgkin lymphoma Y Liu, A van den Berg, R Veenstra, B Rutgers, I Nolte, G van Imhoff, ... Plos one 8 (8), e72930, 2013 | 10 | 2013 |
| Chromatin-remodeled state in lymphoma Y Liu, Y Gonzalez, JE Amengual Current hematologic malignancy reports 14, 439-450, 2019 | 6 | 2019 |
| DUAL INHIBITION OF EZH2 AND HDAC IS SYNERGISTIC IN EZH2 DYSREGULATED LYMPHOMAS JK Lue, SA Prabhu, Y Liu, A Verma, O Elemento, JE Amengual | 6 | 2017 |
| Hypomethylating agents in lymphoma JC Cogan, Y Liu, JE Amengual Current treatment options in oncology 21, 1-9, 2020 | 5 | 2020 |
| Strategy for overcoming Crebbp and EP300 mutations in lymphoma: Development of first-in-class HAT activators Y Liu, J Fiorito, Y Gonzalez, B Estrella, E Calcagno, E Zuccarello, ... Blood 134, 4068, 2019 | 5 | 2019 |
| Epigenetic Targeting with EZH2 and HDAC inhibitors Is Synergistic in EZH2 Deregulated Lymphomas Lue JK, Prabhu SA, Liu Y, O’Connor OA, Amengual JE 2016 ASH annual meeting, Blood 128 (22), 839, 2016 | 5* | 2016 |
| Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia J Sarno, P Domizi, Y Liu, M Merchant, CB Pedersen, D Jedoui, A Jager, ... Nature Communications 14 (1), 2935, 2023 | 4 | 2023 |
| Single-cell technologies uncover intra-tumor heterogeneity in childhood cancers YC Lo, Y Liu, M Kammersgaard, A Koladiya, TJ Keyes, KL Davis Seminars in Immunopathology 45 (1), 61-69, 2023 | 4 | 2023 |
| The Pralatrexate-Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Amengual JE, Lichtenstein R, Rojas C, Sawas A, Deng C, Lichtenstein E, Kahn ... 2016 ASH annual meeting, Blood 128 (22), 1824, 2016 | 4* | 2016 |
| FIRST‐IN‐CLASS HAT ACTIVATOR HIGHLY SYNERGISTIC WITH PAN‐HDAC INHIBITOR ROMIDEPSIN LEADING TO PROFOUND HISTONE ACETYLATION CYTOTOXICITY Y Liu, J Fiorito, Y Gonzale, E Zuccarello, E Calcagno, JM Camarillo, PM ... Hematological Oncology 37 (S2), 125-126, 2019 | 3 | 2019 |
Jennifer E AmengualColumbia UniversityVerified email at columbia.edu
